Dr. Blue on the Utility of Carfilzomib in Relapsed/Refractory Multiple Myeloma


In Partnership With:

Brandon Blue, MD, discusses the utility of carfilzomib in relapsed/refractory multiple myeloma.

Brandon Blue, MD, oncologist, Malignant Hematology, Health Outcomes and Behavior Program, Moffitt Cancer Center, discusses the utility of carfilzomib (Kyprolis) in relapsed/refractory multiple myeloma.

Bortezomib (Velcade) and carfilzomib should be considered for patients who are sensitive to proteasome inhibitors (PI), Blue explains. If a patient has a good response with frontline bortezomib, using carfilzomib, a second-generation PI, could be used. Carfilzomib can be used in combination with multiple agents, including daratumumab (Darzalex), isatuximab-irfc (Sarclisa), and pomalidomide (Pomalyst), Blue says.

Several options can be utilized to capitalize on the mechanism of action associated with PIs, Blue continues. Moreover, PIs have demonstrated a progression-free survival advantage, as well as increased rates of minimal residual negativity, which is associated with improved outcomes for patients, Blue concludes.

Related Videos
Matthew Pierre Deek, MD
Bradford (Brad) S. Hoppe, MD, MPH
Michael Chuong, MD, FACRO,
Jiye Liu, MD
Mitchell Machtay, MD, associate dean, Clinical Cancer Research, professor, endowed Chair in Cancer Clinical Research, Department of Radiation Oncology, professor, Department of Medicine, Penn State College of Medicine
Biagio Ricciuti, MD
Damon R. Reed, MD
Ana Velázquez Mañana, MD
Jeremy C. Jones, MD
Related Content